Effect of human leukocyte interferon on HBsAg production in PLC/PRF/5 human hepatoma cell line

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis B virus (HBV) infection is a significant global health concern.
• Hepatitis B surface antigen (HBsAg) is a key marker of HBV infection.
• Interferon alfa (IFN alfa) is a cytokine with known antiviral properties.

Purpose of the Study:

• To investigate the effect of natural human interferon alfa (HuIFN alfa) on HBsAg production.
• To determine the dose-dependency and duration of HuIFN alfa's effect on HBsAg production.
• To assess the impact of cell confluency on the sensitivity to HuIFN alfa.

Main Methods:

• Treatment of PLC/PRF/5 cells with varying concentrations of HuIFN alfa (3-300 IU/ml).
• Measurement of HBsAg production at 48-hour intervals post-treatment.
• Comparison of HuIFN alfa sensitivity between non-confluent and confluent cell cultures.

Main Results:

• A consistent decrease in HBsAg production was observed 48 hours after HuIFN alfa treatment.
• The reduction in HBsAg production persisted for an additional 24-48 hours, influenced by the IFN dose.
• No significant difference in sensitivity to HuIFN alfa was found between non-confluent and confluent cells.
• The reduction in extracellular HBsAg excretion correlated with the inhibition of intracellular HBsAg formation.

Conclusions:

• Natural HuIFN alfa effectively suppresses HBsAg production in PLC/PRF/5 cells.
• The antiviral effect is dose-dependent and sustained, suggesting therapeutic potential.
• Cell confluency does not alter the cellular response to HuIFN alfa treatment.